
BCLI
Brainstorm Cell Therapeutics Inc
- Overview
- Forecast
- Valuation

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.230
Open
1.230
VWAP
1.14
Vol
100.36K
Mkt Cap
7.44M
Low
1.110
Amount
114.16K
EV/EBITDA(TTM)
--
Total Shares
68.34M
EV
7.71M
EV/OCF(TTM)
--
P/S(TTM)
--
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimers disease (AD) and other neurodegenerative diseases. NurOwn, the Company’s cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its Phase III ALS and Phase II PMS clinical trials. Its wholly owned Israeli subsidiary, BrainStorm Cell Therapeutics Ltd., holds rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd. and two others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q2
--
--
-0.270
-82%
--
--
-0.440
-26.67%
Estimates Revision
The market is revising No Change the revenue expectations for Brainstorm Cell Therapeutics Inc. (BCLI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -38.04%.
EPS Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Down

-38.04%
In Past 3 Month
1 Analyst Rating

426.32% Upside
Wall Street analysts forecast BCLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCLI is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

426.32% Upside
Current: 1.140

Low
6.00
Averages
6.00
High
6.00

426.32% Upside
Current: 1.140

Low
6.00
Averages
6.00
High
6.00
Maxim Group
Jason McCarthy
Hold
to
Strong Buy
Upgrades
$2
2024-07-11
Reason
Maxim Group
Jason McCarthy
Price Target
$2
2024-07-11
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Brainstorm Cell Therapeutics Inc (BCLI.O) is -0.55, compared to its 5-year average forward P/E of -4.60. For a more detailed relative valuation and DCF analysis to assess Brainstorm Cell Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.60
Current PE
-0.55
Overvalued PE
-1.15
Undervalued PE
-8.05
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.35
Current EV/EBITDA
-0.59
Overvalued EV/EBITDA
0.34
Undervalued EV/EBITDA
-1.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
5.04
Current PS
0.00
Overvalued PS
16.03
Undervalued PS
-5.94
Financials
Annual
Quarterly
FY2024Q4
YoY :
-33.62%
-3.19M
Operating Profit
FY2024Q4
YoY :
-46.70%
-2.97M
Net Income after Tax
FY2024Q4
YoY :
-67.90%
-0.52
EPS - Diluted
FY2024Q4
YoY :
-68.10%
-1.05M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
22.1K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
11.3K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
22.1K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
11.3K
USD
Months
0-12
0
0.0
USD
Months
BCLI News & Events
Events Timeline
2025-04-10 (ET)
2025-04-10
07:32:26
BrainStorm submits IND amendment to FDA for Phase 3b trial of NurOwn in ALS

2025-03-26 (ET)
2025-03-26
08:16:38
BrainStorm granted compliance extension from Nasdaq

2024-12-03 (ET)
2024-12-03
06:04:08
BrainStorm receives Notice of Allowance for patent on exosome technology

Sign Up For More Events
Sign Up For More Events
News
9.5
05-07NewsfilterBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
9.0
05-06PRnewswireBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
9.0
04-29NewsfilterBrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
Sign Up For More News
People Also Watch

WMT
Walmart Inc
96.830
USD
+0.99%

AAPL
Apple Inc
212.330
USD
-0.28%

XOM
Exxon Mobil Corp
108.480
USD
-0.90%

ORCL
Oracle Corp
162.950
USD
+0.42%

AVGO
Broadcom Inc
232.120
USD
-0.13%

NVDA
NVIDIA Corp
135.340
USD
+4.16%

AMZN
Amazon.com Inc
210.250
USD
-0.53%

MSFT
Microsoft Corp
452.940
USD
+0.85%

META
Meta Platforms Inc
659.360
USD
+0.51%

TSLA
Tesla Inc
347.680
USD
+4.07%
FAQ

What is Brainstorm Cell Therapeutics Inc (BCLI) stock price today?
The current price of BCLI is 1.14 USD — it has decreased -5.79 % in the last trading day.

What is Brainstorm Cell Therapeutics Inc (BCLI)'s business?

What is the price predicton of BCLI Stock?

What is Brainstorm Cell Therapeutics Inc (BCLI)'s revenue for the last quarter?

What is Brainstorm Cell Therapeutics Inc (BCLI)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Brainstorm Cell Therapeutics Inc (BCLI)'s fundamentals?

How many employees does Brainstorm Cell Therapeutics Inc (BCLI). have?
